This website uses cookies to improve your experience. Continue if you are OK with this or read more in our privacy policy. 

Myriad: the oral arguments


On Monday, April 15, the US Supreme Court heard oral arguments on whether genetic material is patent eligible subject matter and in particular, whether Utah-based Myriad Genetics’ patents covering isolated human genes linked to breast and ovarian cancer are valid and enforceable.

Myriad, gene patents, US Supreme Court, oral arguments, BRCA1


Payment types accepted